Viwit platform provides CDMO services of APIs and intermediates, oral solids (tablets, capsules), sterile liquid products (small volume injections-ampoules, vials, eye drops). The production facilities comply with the cGMP regulations of China's NMPA, US FDA and EU EMA.

The platform's existing CDMO resources include:

1. API facility that was successfully audited by US FDA and Health Canada;

2. US FDA cGMP oral solids production facility that can produce tablets, capsules and other dosage forms;

3. Sterile injectables (ampoules) facility that was GMP certified by China NMPA;

4. Production workshops for injectables (vials) and opthalmic eye drops (single-dose and multi-dose) which are being built in accordance with FDA standards

The CDMO services currently available on the platform include:

1. R&D services

 1) Contract R&D of FDFs: tablets and capsules (IR/ER/DR), injections, eye drops, nano/microsphere products;

 2) Contract R&D of APIs: chemically synthesized APIs or semi-synthetic APIs;

 3) Contract R&D of intermediates for innovative medicines.

2. Contract production services of

 1) FDFs: tablets, capsules, oral powders, injections;

 2) APIs: chemically synthesized APIs or semi-synthetic APIs;

 3) Pharmaceutical intermediates.